Categories Earnings, Health Care

BioLineRx (BLRX): Q3 2019 Earnings Snapshot

—  BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period.

— Net loss per share was cents per share, narrower than a loss of 6 cents per share last year, due to higher share count.

— R&D expenses rose 11% to $5.6 million, primarily due to costs associated with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results expected by the end of the year.

— BLRX shares are down 75% so far this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

McDonald’s (MCD) Earnings: Q2 profit jumps and tops expectations on 57% sales growth

McDonald’s Corporation (NYSE: MCD) Wednesday reported stronger-than-expected earnings and revenues for the second quarter of 2021. The fast-food chain reported revenues of $5.89 billion for the June quarter, up 57%

Key highlights from Shopify Q2 earnings: Infographic

Shopify (NYSE: SHOP) reported second-quarter 2021 financial results before the regular market hours on Wednesday. The ecommerce giant reported Q2 revenue of $1.12 billion, up 57% year-over-year and higher than

Infographic: How Pfizer (PFE) performed in Q2 2021

Pfizer Inc. (NYSE: PFE) reported second quarter 2021 earnings results today. Total revenue increased 92% year-over-year to $19 billion. GAAP net income increased 59% YoY to $5.5 billion, or $0.98

Add Comment
Viewing Highlight